Last reviewed · How we verify
NCT00771043: PRTOECT
A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
Phase 4 trial testing TYSABRI and AVONEX in Relapsing-remitting Multiple Sclerosis. Withdrawn.
1 August 2009
Quick facts
| Lead sponsor | Biogen |
|---|---|
| Phase | Phase 4 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 November 2008 |
| Primary completion | 1 August 2009 |
| Estimated completion | 1 June 2010 |
Drugs / interventions tested
- TYSABRI and AVONEX — full drug profile →
Conditions studied
- Relapsing-remitting Multiple Sclerosis — all drugs for Relapsing-remitting Multiple Sclerosis →
Sponsor
Biogen — full company profile →
Who can join
Adults 18 to 55, any sex, with Relapsing-remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase IV, proof-of-concept, randomized, open-label, multi-center, two-arm, 9-month study to evaluate the neuroprotective effects of Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of acute optic neuritis (AON) as measured by RNFL thickness from Optical Coherence Tomography in patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00771043
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsing-remitting Multiple Sclerosis
Currently open trials in the same condition.
- NCT05758831 — RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. · Phase 3 · recruiting
- NCT05755061 — WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis · Phase 1 · active not recruiting
- NCT06586177 — Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies · recruiting
Other Biogen trials
Trials by the same sponsor.
- NCT07483632 — A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses · Phase 3 · not yet recruiting
- NCT06628687 — A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it Duri · recruiting
- NCT07444450 — A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy · Phase 3 · not yet recruiting
- NCT07444489 — A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants · Phase 3 · not yet recruiting
- NCT07444476 — A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years Wit · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00771043 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biogen
- Last refreshed: 3 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00771043.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing